121 related articles for article (PubMed ID: 33788715)
1. The Impact of Insulin on Low-dose Metronomic Vinorelbine and Mafosfamide in Breast Cancer Cells.
Krajnak S; Loewe A; Battista MJ; Hasenburg A; Heimes AS; Schmidt M; Schwab R; Brenner W
Anticancer Res; 2021 Mar; 41(3):1243-1250. PubMed ID: 33788715
[TBL] [Abstract][Full Text] [Related]
2. A Dose-finding Study of Metronomic Oral Vinorelbine in Combination With Oral Cyclophosphamide and Bevacizumab in Patients With Advanced Breast Cancer.
Sanna G; Pestrin M; Moretti E; Biagioni C; De Santo I; Gabellini S; Galardi F; McCartney A; Biganzoli L
Clin Breast Cancer; 2021 Aug; 21(4):e332-e339. PubMed ID: 33353853
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumor effects of low-dose metronomic vinorelbine in combination with alpelisib in breast cancer cells.
Krajnak S; Trier JP; Heinzmann PF; Anic K; Heimes AS; Loewe A; Schmidt M; Battista MJ; Hasenburg A; Brenner W
EXCLI J; 2023; 22():114-130. PubMed ID: 36998707
[TBL] [Abstract][Full Text] [Related]
4. Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial.
Adamo B; Bellet M; Paré L; Pascual T; Vidal M; Pérez Fidalgo JA; Blanch S; Martinez N; Murillo L; Gómez-Pardo P; López-González A; Amillano K; Canes J; Galván P; González-Farré B; González X; Villagrasa P; Ciruelos E; Prat A
Breast Cancer Res; 2019 Sep; 21(1):108. PubMed ID: 31533777
[TBL] [Abstract][Full Text] [Related]
5. Treatment of advanced breast cancer with a metronomic schedule of oral vinorelbine: what is the opinion of Italian oncologists?
Cazzaniga ME; Munzone E; Montagna E; Pappagallo G
Expert Rev Anticancer Ther; 2018 Aug; 18(8):805-814. PubMed ID: 29902087
[TBL] [Abstract][Full Text] [Related]
6. Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma.
Orecchioni S; Talarico G; Labanca V; Calleri A; Mancuso P; Bertolini F
Br J Cancer; 2018 May; 118(10):1329-1336. PubMed ID: 29695766
[TBL] [Abstract][Full Text] [Related]
7. Unfavorable prognostic role of tumor-infiltrating lymphocytes in hormone-receptor positive, HER2 negative metastatic breast cancer treated with metronomic chemotherapy.
Montagna E; Vingiani A; Maisonneuve P; Cancello G; Contaldo F; Pruneri G; Colleoni M
Breast; 2017 Aug; 34():83-88. PubMed ID: 28544923
[TBL] [Abstract][Full Text] [Related]
8. Metronomic therapy in advanced breast cancer and NSCLC: vinorelbine as a paradigm of recent progress.
Xu B; Sun T; Wang S; Lin Y
Expert Rev Anticancer Ther; 2021 Jan; 21(1):71-79. PubMed ID: 33054438
[TBL] [Abstract][Full Text] [Related]
9. Low-dose metronomic chemotherapy as an efficient treatment option in metastatic breast cancer-results of an exploratory case-control study.
Krajnak S; Schnatz C; Almstedt K; Brenner W; Haertner F; Heimes AS; Lebrecht A; Makris GM; Schwab R; Hasenburg A; Schmidt M; Battista MJ
Breast Cancer Res Treat; 2020 Jul; 182(2):389-399. PubMed ID: 32495001
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy study of metronomic vinorelbine, cyclophosphamide plus capecitabine in metastatic breast cancer: A phase II trial.
Montagna E; Palazzo A; Maisonneuve P; Cancello G; Iorfida M; Sciandivasci A; Esposito A; Cardillo A; Mazza M; Munzone E; Lai A; Goldhirsch A; Colleoni M
Cancer Lett; 2017 Aug; 400():276-281. PubMed ID: 28131905
[TBL] [Abstract][Full Text] [Related]
11. Dual‑directional effect of vinorelbine combined with cisplatin or fluorouracil on tumor growth and metastasis in metronomic chemotherapy in breast cancer.
Liu H; Li M; Lin Y; You H; Kou J; Feng W
Int J Oncol; 2024 Feb; 64(2):. PubMed ID: 38063236
[TBL] [Abstract][Full Text] [Related]
12. The NAME trial: a direct comparison of classical oral Navelbine versus Metronomic Navelbine in metastatic breast cancer.
Langkjer ST; Kenholm J; Jensen JD; Wedervang K; Brixen AT; Grunnet M; Stenbygaard L; Gilje B; Danø H; Glavicic V; Jacobsen EH; Brems-Eskildsen AS; Kruse HL; Dongsgaard T; Neimann J; Geisler J
Future Oncol; 2019 Aug; 15(22):2561-2569. PubMed ID: 31215242
[TBL] [Abstract][Full Text] [Related]
13. [A patient with subcutaneous, lymph node and bone lesions for breast cancer: a progressive response to metronomic oral vinorelbine and capecitabine.].
Ghilardi M
Recenti Prog Med; 2019 Oct; 110(10):490-493. PubMed ID: 31657815
[TBL] [Abstract][Full Text] [Related]
14. Metronomic chemotherapy for advanced breast cancer patients.
Cazzaniga ME; Dionisio MR; Riva F
Cancer Lett; 2017 Aug; 400():252-258. PubMed ID: 28017894
[TBL] [Abstract][Full Text] [Related]
15. [A patient with subcutaneous, lymph node and bone lesions for breast cancer: a progressive response to metronomic oral vinorelbine and capecitabine.].
Ghilardi M
Recenti Prog Med; 2019 Dec; 110(12):27e-30e. PubMed ID: 31909766
[TBL] [Abstract][Full Text] [Related]
16. Metronomic chemotherapy in the neoadjuvant setting: results of two parallel feasibility trials (TraQme and TAME) in patients with HER2+ and HER2- locally advanced breast cancer.
Petry V; Gagliato DM; Leal AI; Arai RJ; Longo E; Andrade F; Ricci MD; Piato JR; Barroso-Sousa R; Hoff PM; Mano MS
Braz J Med Biol Res; 2015 May; 48(5):479-85. PubMed ID: 25760024
[TBL] [Abstract][Full Text] [Related]
17. Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current status and future development.
Cazzaniga ME; Camerini A; Addeo R; Nolè F; Munzone E; Collovà E; Del Conte A; Mencoboni M; Papaldo P; Pasini F; Saracchini S; Bocci G
Future Oncol; 2016 Feb; 12(3):373-87. PubMed ID: 26584409
[TBL] [Abstract][Full Text] [Related]
18. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
[TBL] [Abstract][Full Text] [Related]
19. Immunomodulatory effects of metronomic vinorelbine (mVRL), with or without metronomic capecitabine (mCAPE), in hormone receptor positive (HR+)/HER2-negative metastatic breast cancer (MBC) patients: final results of the exploratory phase 2 Victor-5 study.
Pepe FF; Cazzaniga ME; Baroni S; Riva F; Cicchiello F; Capici S; Cogliati V; Maggioni C; Cordani N; Cerrito MG; Malandrin S
BMC Cancer; 2022 Sep; 22(1):956. PubMed ID: 36068484
[TBL] [Abstract][Full Text] [Related]
20. A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer.
Saridaki Z; Malamos N; Kourakos P; Polyzos A; Ardavanis A; Androulakis N; Kalbakis K; Vamvakas L; Georgoulias V; Mavroudis D
Cancer Chemother Pharmacol; 2012 Jan; 69(1):35-42. PubMed ID: 21590447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]